Apellis Pharmaceuticals developed SYFOVRE™ (pegcetacoplan injection) for the treatment of secondary age-related macular degeneration (AMD).
SYFOVRE™ (pegcetacoplan injection) is the only therapy approved for geographic atrophy (GA). By targeting C3, pegcetacoplan is designed to provide comprehensive control of the complement cascade, part of the body’s immune system.
With the flexibility of 25-60 minute dosing, SYFOVRE makes a significant difference in the lives of GA patients.
There are no approved therapy for GA patients living with impaired vision. The approval of SYFOVRE, will be the safe and effective GA treatment for this devastating disease with increasing effects over time.
GA is a leading cause of blindness. It is an advanced form of age-related macular degeneration and is a progressive and irreversible disease caused by the growth of lesions, which destroy the retinal cells responsible for vision affecting quality of life, and restricting daily activities.
U.S. Food and Drug Administration (FDA) approved SYFOVRE™ (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
